Participated · Series A · Feb 2022

Founded in 2014, Damae Medical’s mission is to let dermatologists observe skin at the cellular scale directly during consultations. Its core product, deepLive™, delivers instant, non-invasive cellular imaging supported by a real-time, CE-certified AI engine. Backed by more than a decade of R&D and over 250 scientific publications, deepLive™ is already installed in 120+ sites across 15+ countries, spanning hospitals and private practices. The system is used from initial diagnosis to intra-operative surgical guidance, helping thousands of patients avoid unnecessary biopsies, repeat surgeries and long waiting times. With the technology now commercially launched, the company plans to broaden access beyond early pioneer centers and make digital biopsy a routine part of dermatological care. The newly secured Series B funding strengthens its financial position and fuels this expansion. Damae Medical continues to focus on accelerating adoption, improving accuracy and reducing invasiveness in skin-cancer management.

Participated · Series B · Jan 2020

Sensome develops sensing technology that combines micro‑sensors with machine‑learning to instantly identify biological tissues upon contact and turn invasive medical tools into connected devices. The company’s first product is a guidewire called Clotild; with the new funding it will test Clotild’s clinical performance and prepare the product for market. Sensome was founded in 2014 as a spin‑off from CNRS and École Polytechnique and is based in France. The startup has partnered with Asahi Intecc on a two‑year development plan to design a new connected guidewire for ischemic stroke treatment. That collaboration includes integrating Sensome’s tissue sensor into Asahi’s Chikai guidewire to improve first‑try clot removal. The company raised Series B capital to fund clinical testing and product development. Sensome builds impedance-based micro-sensors combined with machine learning to instantly identify biological tissues, a capability the company says offers unequaled predictive reliability. The sensors are extremely thin and can be integrated into existing medical devices. Its first product, Clotild™, is a connected guidewire designed to determine clot content during ischemic stroke interventions to help physicians select optimal tools and reestablish blood flow. The company says Clotild™ targets faster, more informed stroke treatment and will undergo clinical testing. Sensome plans to bring Clotild™ to the European market and to explore additional applications of its sensing technology. Sensome recently completed a €4.6 million financing round to support these clinical and market efforts.

Participated · Series A · Sep 2019

FeetMe develops smart medical wearables—connected insoles—combined with pressure sensors, motion sensors and learning algorithms to perform real-world gait and posture analysis. The company positions its platform as the world’s first and most advanced solution for real-world disease diagnostics, monitoring and rehabilitation based on movement data. FeetMe says its technology can generate unique insights and real-world evidence to accelerate clinical research at scale and to empower rehabilitation for patients with gait disorders. The fundraising will be used to develop new digital health services and accelerate commercial activities in clinical trials for the pharmaceutical industry and for hospitals and rehabilitation facilities worldwide. The company notes that about 100 million people globally suffer from gait disorders, which are indicators for conditions such as multiple sclerosis, Parkinson’s disease, peripheral neuropathies and diabetic foot problems. FeetMe is a certified medical device company focused on long-term continuous mobility assessment and building large gait-pattern datasets to enable new digital biomarkers. FeetMe is a Paris, France-based medical device company led by founder and CEO Alexis Mathieu. The company produces smart and connected insoles that combine pressure sensors, motion sensors and learning algorithms to analyze patients’ functional capacity and support running, walking and gait analysis. Its technology is positioned to empower rehabilitation among sufferers of gait disorders. FeetMe raised €1.95m in seed funding to advance product development. The company intends to use the funds to pursue development of its product to target therapeutic areas in collaboration with market players. The financing includes participation from strategic and specialty healthcare investors.